What people are saying - Write a review
We haven't found any reviews in the usual places.
By Jack M Gorman MD
IntroductionNovel Perspectives of Central CRFHPA Axis Medicine
members in 30 countries
6 other sections not shown
abnormal activity administration adverse events agents agonists amphetamines anorexia antagonists antidepressants antipsychotic anxiety disorders ARICEPT associated baseline behavioral brain carbamazepine Cardiovascular cell Cetexa chronic clinical studies clinical trials CNS Spectrums cognitive compared controlled trials Cortisol decreased discontinuation disease dizziness donepezil dosage edema effects efficacy enzymes epilepsy evaluated Exelon Frequent gabapentin galantamine GEODON glutamate hepatic HPA axis hypericum hypotension impaired incidence increased Infrequent inhibition inhibitors insomnia interactions kava Keppra lamotrigine levels levetiracetam major depression Medical metabolism mg/day mg/kg/day monoamine MRHD nausea Nervous System neurons Neurontin noradrenergic norepinephrine obesity occurred oral paroxetine patients treated Paxil pediatric pharmacokinetic phenytoin placebo placebo patients placebo-controlled plasma potential Pregnancy prescribing information protein Psychiatry quetiapine rats receptor REMINYL reported response risk RISPERDAL risperidone rivastigmine schizophrenia seizures SEROQUEL serotonin serum significant somnolence stress symptoms syndrome therapy titration treated patients treatment urinary valerian vitro vomiting weight yohimbine